UNSPSC 51373008: Phenazocine hydrobromide

This classification denotes an opioid analgesic and narcotic C22H27NO.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C1749020IH, chemically known as 2'-hydroxy-5,9-dimethyl-2-phenethyl-6,7-benzomorphan, hbr, but more generally known as phenazocine hydrobromide, which bears US NIH Compound Identifier 14706. European Medicines Agency schedules Phenazocine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03734MIG.

Most nations, for tariff and trade purposes, schedule phenazocine hydrobromide under HS 29333999 and SITC 51574. As of Q4 2014, PHENAZOCINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Phenazocine hydrobromide bears US NLM identifiers UMLS ID C0600121 and NCI Concept Code C96729. SMILES: C[C@H]1[C@H]2CC3CCC(CC3[C@@]1(CCN2CCC4CCCCC4)C)O.BR.

UNSPSC 51373008 Phenazocine hydrobromide is a Commodity code that nominally covers a single opioid pharmaceutical product, but recent state and local procurement activity under this code shows little alignment with the specific drug named. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products — none of which are phenazocine. State and local governments appear to be using this code as a general pharmaceutical or controlled-substance procurement category rather than for phenazocine specifically. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving participating state and local facilities including Oregon).

Recent activity spans Florida, Texas, and Minnesota through a cooperative purchasing vehicle. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a response deadline of July 26, 2023 (note: the due date appears inconsistent with the posting date). The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities outside traditional PBM and GPO channels. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with contract effectiveness July 1, 2026. The mismatch between the code's nominal scope and actual solicitation content suggests either systematic miscoding of pharmaceutical procurements or that this code serves as a catch-all for state and local drug-related purchasing that does not fit narrower categories.